Kwang-Wei Wu

Kwang-Wei Wu

Takeda Pharmaceutical Company Limited - Osaka / Japan
Medical and Health Sciences / Medical Oncology
AD Scientific Index ID: 4864094
武田薬品工業株式会社
person_outline Kwang-Wei Wu's MOST POPULAR ARTICLES
1-) Improved response rates with bortezomib in relapsed or refractory multiple myeloma: an observational study in Chinese patientsMF Lin, J Hou, WM Chen, XJ Huang, ZG Liu, YH Zhou, Y Li, T Zhao, ...Advances in therapy 31 (10), 1082-1094, 2014122014
2-) Impact of ixazomib‐lenalidomide‐dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging‐markets subgroup of the TOURMALINE‐MM1 trialA Spencer, O Samoilova, WJ Chng, R Labotka, C Li, KW Wu, N Saxena, ...EJHaem 3 (4), 1241-1251, 202212022
3-) Treatment patterns and clinical outcomes in patients with relapsed/refractory hodgkin lymphoma receiving stem cell transplantation outside europe and north america: Results …M Al-Mansour, B Ferhanoglu, M Zerga, D Brittain, SP Yeh, G Tumyan, ...BONE MARROW TRANSPLANTATION 57 (SUPPL 1), 301-302, 20222022
4-) Use of Positron Emission Tomography in Patients with Classical Hodgkin Lymphoma Outside of Europe and North America: Results from the International, Multi-Center, Retrospective …B Ferhanoglu, M Zerga, M Al-mansour, TM Kim, SP Yeh, Y Song, ...Blood 138, 1397, 20212021
5-) Protocol for an International, Multi-Centre, Retrospective Study to Describe Treatment Pathways, Outcomes and Resource Use in Patients with Multiple Myeloma (INTEGRATE)SP Yeh, F Alsharif, M Beksac, W Chen, D Fantl, T Mitina, E Verburgh, ...Blood 134, 5577, 20192019